Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Canadian Institutes of Health Research (CIHR) | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients who receive tailored navigation (consisting of a letter and patient navigation services) and get screened will be significantly greater than the control group who receives treatment as usual.
A majority of patients will opt for Fecal Occult Blood Testing (FOBT)as one of their preferred tests, after undergoing the "Patient Navigator" intervention and that proportion will be significantly greater than the group who opt for FOBT in the control group.
Primary Outcome Measure:
Number of patients who receive a letter and patient navigation services and get screened compared to the control group.
Secondary Outcome Measures:
Proportion (%) of patients preferring FOBT vs.colonoscopy; Predictors of CRC screening and screening preference.
Subjects: Ambulatory patients (men-women aged 50 years and above) recruited from primary care practices at the Group Health Centre, Sault Ste Marie, Ontario. All patients will be screened for eligibility and those who are eligible and agree to participate in the study will be randomized to either of the two study arms: intervention group or control group.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Navigator intervention | Experimental |
| |
| Usual Care Control | Active Comparator | Usual care |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Health counselling by nurse navigator | Behavioral | Information on colorectal cancer and screening, assistance in selection of screening option and obtaining kit or colonoscopy referral |
| Measure | Description | Time Frame |
|---|---|---|
| Completion of verified CRC screening event (FOBT;colonoscopy) event in experimental vs. control groups within 48 weeks | Completion of verified CRC screening events in experimental vs. control patients | 48 weeks after baseline assessment |
| Measure | Description | Time Frame |
|---|---|---|
| Screening preferences; predictors of CRC screening and screening preference. | 48 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Paul Ritvo, PHD | Cancer Care Ontario | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Group Health Centre | Sault Ste. Marie | Ontario | Canada |
Not provided
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| ID | Term |
|---|---|
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Usual primary care counselling | Behavioral | Usual care health counselling on colorectal cancer and screening options |
|
|
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |